TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02401126

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate supplementation
Description: Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
Study: NCT00500487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 12-session group intervention including affect management training as well as sexual health skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Prevention Skills
Description: 12-session group intervention including sexual health skills training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 12-session group intervention including health information on a variety of health topics.
Study: NCT03372538

Intervention type: PROCEDURE
Intervention: cesarean section or cesarean hysterectomy
Description: upper segment cesarean section and or cesarean hysteroctomy

Intervention type: PROCEDURE
Intervention: cesarean section or cesarean hysterectomy
Description: upper segment cesarean section and or cesarean hysteroctomy
Study: NCT03209882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TILS
Description: Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TILS
Description: Continuous-wave laser of a specific wavelength (1064 nm) was administered to the participants' right forehead for 8 minutes. The laser power was 3.4 Watts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham
Description: The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham
Description: The sham session consisted of administering the same laser to the participants' right forehead for totally 8 minutes. However, the laser power was turned to be 0 Watts.
Study: NCT00344552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
Study: NCT00094302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of spironolactone
Study: NCT01029938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Covered stent
Description: Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Covered stent
Description: Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coil
Description: Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coil
Description: Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
Study: NCT03871608

Intervention type: OTHER
Intervention: Examination of functional etiologies on DTM Disorders
Description: Evaluating functional etiologies accessible to rehabilitation, consists of 4 categories (Orofacial dyspraxia, parafunctions, posture, Chewing) and includes 11 items in total

Intervention type: OTHER
Intervention: Assessment of symptoms on DTM Disorders
Description: Examining the symptoms of the patient, consists of 5 categories (Muscle examination, Areas of cellulalgic infiltrates, Mandibular kinetics, Joint sounds, Thrust)and includes 21 items
Study: NCT04175951

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Description: Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Description: Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
Study: NCT04574882

Intervention type: OTHER
Intervention: Survey
Description: Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.

Intervention type: OTHER
Intervention: Survey
Description: Interested participants may complete the informed consent online. After informed consent, the participant will be asked to share the digital data types that they use (Facebook, Instagram, Twitter, Google search, step data) and then participants will complete a cross-sectional survey.
Study: NCT00154102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Description: Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Description: Bi-weekly Irinotecan infusion of 180mg/m\^2, Folinic Acid infusion of 400mg/m\^2 (racemic) or 200mg/m\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\^2 followed by a 46-hour continuous infusion of 2400mg/m\^2 Number of Cycles: until progression or unacceptable toxicity develops
Study: NCT00628160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha adrenergic drugs
Description: Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
Study: NCT02218164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2b
Description: Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
Study: NCT04167566

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Artemisinin Combination Therapy ACTs
Description: All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
Study: NCT02173704

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero®
Description: Four doses administered in the anterolateral area of the right or left thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine vaccines
Description: Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
Study: NCT01138072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: 200mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg Simvastatin single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20 mg Simvastatin single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg atorvastatin single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20 mg atorvastatin single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg rosuvastatin single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg rosuvastatin single dose
Study: NCT02373332

Intervention type: OTHER
Intervention: omega-3 and -6 fatty acids and their 12-LOX oxylipins
Description: platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
Study: NCT03863730

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Profermin Plus, FSMP, probiotics
Description: Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.~The product Profermin Plus® has changed its name to ReFerm®. The content of the product is unchanged. The change occurred after the clinical part of the study was completed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin, dietary supplement
Description: Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
Study: NCT04183881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab 210mg SC
Description: 210 mg, subcutaneous dosing, every 2 weeks
Study: NCT03287050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV q 21 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
Study: NCT04589910

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: diaphragm thickness and thickening fraction
Description: Ultrasound measurement of the diaphragm will be performed with the use of a Sono Site SII, portable system in B mode with the child in a 30-degree supine position. The diaphragm thickness will be measured with a high frequency (4-10 MHz) linear array transducer placed in the ninth or tenth intercostal space between the anterior and midaxillary lines in the zone of apposition between lung and liver.
Study: NCT01147952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training
Description: randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
Study: NCT01648010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 gel
Description: One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TC-3 gel mixed with Mitomycin C (MMC)
Description: One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
Study: NCT00866242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
Description: The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
Study: NCT04344418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nurse-performed Focused cardiac ultrasound (FoCUS)
Description: A FoCUS-trained nurse will perform a FoCUS examination within 30 minutes of triage by the triage clinician. The Philips Lumify® handheld ultrasound device (HUD) with a phased array probe will be used and studies limited to a maximum of 10 minutes each. A presumptive diagnosis will then be selected by the nurse from a FoCUS checklist based on pre-defined thresholds for each FoCUS target condition and the time the diagnosis is made recorded. Additional imaging and lab tests may be requested at the discretion of the clinical team but the FoCUS nurses will be blinded to the results of these.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control arm will consist of usual care ie a combination of physical examination, lab tests and imaging. The need for a formal echocardiographic evaluation by a cardiologist or cardiac sonographer in patients assigned to the control arm will be at the discretion of the clinical teams, as is usual care at KNH and AKUHN
Study: NCT04292561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low MAC
Description: To maintain a target of sevoflurane inhalation concentration 0.8 MAC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High MAC
Description: To maintain a target of sevoflurane inhalation concentration 1.0 MAC.
Study: NCT03186911

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: E-liquid sampling and preference assessment
Description: Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
Study: NCT01137695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide
Description: 120 mcg SQ three times daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: 360 mcg SQ three times daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide
Description: 120 mcg SQ three times daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: 360 mcg SQ three times daily for 6 months
Study: NCT03818802

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
Study: NCT01450709

Intervention type: DIETARY_SUPPLEMENT
Intervention: Kibow Biotics
Description: 6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
Study: NCT03510559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forearm Nerve Block
Description: Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brachial Plexus Block
Description: Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
Study: NCT02564263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg administered as IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80-100 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m\^2 administered as IV infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: 180 mg/m\^2 administered as IV infusion on Day 1 of every 14-day cycle
Study: NCT00442910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% SPL7013 Gel (VivaGel)
Description: 3% vaginal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo for SPL7013 gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo Gel
Description: HEC Placebo gel intravaginally bd for 14 days
Study: NCT02101541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FIRM ablation
Description: Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
Study: NCT00784849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: 1 mC1
Study: NCT01113268

Intervention type: OTHER
Group type: OTHER
Intervention: Cohort
Description: Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
Study: NCT01742975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IFABOND (TM)
Description: The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
Study: NCT02844153

Intervention type: OTHER
Intervention: modalities of metformin prescription
Description: Metformin prescription or not, in each CKD stage
Study: NCT03532685

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric
Description: withdrawing a part of the stomach and may or may not be combined with bowel deviation
Study: NCT02445664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Video: Information on osteoporosis and alendronate treatment.
Study: NCT04669210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib administered during conditioning 5 mg tid before allogeneic hematopoietic stem cell transplantation, 5 mg tid days 5-21 and 5 mg bid days 22-150 after transplantation instead of tacrolimus and MMF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus 0.03 mg/kg adjusted to concentrations 5-15 ng/ml from day+5 to +100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil 30 mg/kg from day +5 to +35
Study: NCT03767088

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS
Description: whole body electromyostimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WB-EMS
Description: whole body electromyostimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: (synchronized) Training program without WB-EMS
Description: 20 min of pronounced eccentric movement patterns
Study: NCT01239251

Intervention type: OTHER
Intervention: GlowCap device
Description: Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
Study: NCT03061409

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pharmavite Nature Made Multi for Him 50+
Description: To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: served as placebo